Mirikizumab

DB14910

biotech approved investigational

Deskripsi

Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis. It inhibits the actions of interleukin-23 (IL-23), a pro-inflammatory cytokine that activates pathways contributing to the development of inflammatory diseases.L46237,L46257

Mirikizumab is approved in JapanL46252 and received a positive opinion from the EMA's Committee for Medicinal Products for Human Use in March 2023.L46237 In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns.L46252 It was officially approved in the EU in May 2023L48656 and Canada in July 2023L48661, and was eventually approved in the US in October 2023L48651 for the treatment of adult patients with moderate-to-severely active ulcerative colitis.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The geometric mean elimination half-life in patients with ulcerative colitis was approximately 9.3 days.[L48646]
Volume Distribusi The geometric mean total volume of distribution in patients with ulcerative colitis was approximately 4.83 L.[L48646]
Klirens (Clearance) The geometric mean clearance of mirikizumab was found to be approximately 0.0229 L/h and is independent of dose.[L48646]

Absorpsi

Following subcutaneous administration, the geometric mean absolute bioavailability was 44% and the median Tmax was 5 days.L48646 The site of subcutaneous injection did not significantly influence mirikizumab bioavailability. The estimated steady-state Cmax, AUCtau, and Ctrough of mirikizumab following subcutaneous administration in patients with ulcerative colitis were 10.1 ?g/mL, 160 ?g*day/mL, and 1.70 ?g/mL, respectively.L48646 The estimated steady-state Cmax, AUCtau, and Ctrough of mirikizumab following intravenous infusion in patients with ulcerative colitis were 99.7 ?g/mL, 538 ?g*day/mL, and 2.75 ?g/mL, respectively.L48646

Metabolisme

As with other therapeutic proteins, mirikizumab is likely degraded into smaller peptides and amino acids via catabolic pathways.L48646

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

353 Data
Rubella virus vaccine The risk or severity of adverse effects can be increased when Mirikizumab is combined with Rubella virus vaccine.
Varicella zoster vaccine (live/attenuated) The risk or severity of adverse effects can be increased when Mirikizumab is combined with Varicella zoster vaccine (live/attenuated).
Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Mirikizumab is combined with Bacillus calmette-guerin substrain tice live antigen.
Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Mirikizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.
Yellow fever vaccine The risk or severity of adverse effects can be increased when Mirikizumab is combined with Yellow fever vaccine.
Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Mirikizumab.
Typhoid Vaccine Live The risk or severity of adverse effects can be increased when Mirikizumab is combined with Typhoid Vaccine Live.
Bacillus calmette-guerin substrain danish 1331 live antigen The risk or severity of adverse effects can be increased when Mirikizumab is combined with Bacillus calmette-guerin substrain danish 1331 live antigen.
BCG vaccine The risk or severity of adverse effects can be increased when Mirikizumab is combined with BCG vaccine.
Human adenovirus e serotype 4 strain cl-68578 antigen The risk or severity of adverse effects can be increased when Mirikizumab is combined with Human adenovirus e serotype 4 strain cl-68578 antigen.
Vibrio cholerae CVD 103-HgR strain live antigen The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Mirikizumab.
Adenovirus type 7 vaccine live The risk or severity of adverse effects can be increased when Mirikizumab is combined with Adenovirus type 7 vaccine live.
Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Mirikizumab.
Chikungunya vaccine (live, attenuated) The risk or severity of adverse effects can be increased when Mirikizumab is combined with Chikungunya vaccine (live, attenuated).
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Mirikizumab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Mirikizumab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Mirikizumab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Mirikizumab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Mirikizumab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Mirikizumab.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Mirikizumab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Mirikizumab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Mirikizumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Mirikizumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Mirikizumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Mirikizumab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Mirikizumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Mirikizumab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Mirikizumab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Mirikizumab.
Trastuzumab The risk or severity of neutropenia can be increased when Trastuzumab is combined with Mirikizumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Mirikizumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Mirikizumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Mirikizumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Mirikizumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Mirikizumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Mirikizumab.
Cyclosporine Mirikizumab may increase the immunosuppressive activities of Cyclosporine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Mirikizumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Mirikizumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Mirikizumab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Mirikizumab.
Natalizumab The risk or severity of immunosuppression can be increased when Mirikizumab is combined with Natalizumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Mirikizumab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Mirikizumab.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Mirikizumab.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Mirikizumab.
Cladribine Mirikizumab may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Mirikizumab.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Mirikizumab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Mirikizumab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Mirikizumab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Mirikizumab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Mirikizumab.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Mirikizumab.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Mirikizumab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Mirikizumab.
Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Mirikizumab.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Mirikizumab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Mirikizumab.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Mirikizumab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Mirikizumab.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Mirikizumab.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Mirikizumab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Mirikizumab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Mirikizumab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Mirikizumab.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Mirikizumab.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Mirikizumab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Mirikizumab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Mirikizumab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Mirikizumab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Mirikizumab.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Mirikizumab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Mirikizumab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Mirikizumab.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Mirikizumab.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Mirikizumab.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mirikizumab.
Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Mirikizumab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Mirikizumab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Mirikizumab.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Mirikizumab.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Mirikizumab.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Mirikizumab.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Mirikizumab.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Mirikizumab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Mirikizumab.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Mirikizumab.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Mirikizumab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Mirikizumab.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Mirikizumab.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Mirikizumab.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Mirikizumab.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mirikizumab.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mirikizumab.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Mirikizumab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Mirikizumab.
Mometasone The risk or severity of adverse effects can be increased when Mometasone is combined with Mirikizumab.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Mirikizumab.

Target Protein

Interleukin-23 subunit alpha IL23A

Referensi & Sumber

Link

Contoh Produk & Brand

Produk: 12 • International brands: 0
Produk
  • Omvoh
    Injection, solution, concentrate • 300 mg • Intravenous • EU • Approved
  • Omvoh
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Omvoh
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Omvoh
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Omvoh
    Solution • 100 mg / mL • Subcutaneous • Canada • Approved
  • Omvoh
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Omvoh
    Solution • 100 mg / mL • Subcutaneous • Canada • Approved
  • Omvoh
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
Menampilkan 8 dari 12 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul